Observational studyJournal of the American Heart Association2023
Lipoprotein(a) Testing Trends in a Large Academic Health System in the United States.
Observational study in Journal of the American Heart Association, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 73 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
73 citing papers in PubMed, 106 citations in OpenAlex.
- Lipoprotein(a)-dependent cardiovascular risk in different populations: are thresholds the same?Annals of medicine · 2026Review
- Expert consensus on Lipoprotein(a) in the Gulf countries: Navigating cardiovascular risk and therapeutic advances.Atherosclerosis plus · 2026Article
- Article
- Gaps and disparities in Lp(a) testing before universal screening: A 10-year analysis.International journal of cardiology. Cardiovascular risk and prevention · 2026Article
- Lipoprotein(a) Levels and Major Adverse Cardiovascular Events in Alberta, Canada: A Retrospective Cohort Study.CJC open · 2026Article
- Estimating the indirect economic burden of elevated lipoprotein(a): A 5-year simulation of cardiovascular events and associated patient and caregiver costs.American journal of preventive cardiology · 2026Article
- Lipoprotein(a) in Cardiovascular Diseases and Emerging Therapeutic Strategies.Cardiovascular drugs and therapy · 2026Review
- Global trends in lipoprotein(a) and high-sensitivity c-reactive protein testing in patients with established atherosclerotic cardiovascular disease.American journal of preventive cardiology · 2026Article
- Lipoprotein(a) and Women's Cardiovascular Health: A Review.JACC. Advances · 2026Article
- Enhancing representation in cardiovascular trials: Lessons from Lp(a)FRONTIERS EXPANSION in United States Black and Hispanic patients with elevated lipoprotein(a) and established atherosclerotic cardiovascular disease.American journal of preventive cardiology · 2026Article
- Lipoprotein(a) concentration, kringle IV-2 repeat copy number, and myocardial infarction risk in Chinese populations: insights from the INTERHEART China study.Lipids in health and disease · 2026Article
- Progress in risk assessment and management: Forecasting updates across international cholesterol guidelines.American journal of preventive cardiology · 2026Review
- Biomarkers for Screening and Diagnosis of Heart Failure in Cardiovascular-Kidney-Metabolic Syndrome: A Narrative Review.International journal of molecular sciences · 2026Review
- Lipoprotein(a), apolipoprotein B and other lipid biomarkers in Asian healthcare workers.Lipids in health and disease · 2026Article
- Lipoprotein(a) testing in an outpatient cardiology clinic: A quality improvement initiative.Journal of clinical lipidology · 2026Article
- Genetically Predicted Levels of Lipoprotein(a) and Risk of Cerebrovascular Disease.Journal of the American Heart Association · 2026Article
- The Lipoprotein(a) Implementation Gap: Bridging Evidence and Clinical Practice.Reviews in cardiovascular medicine · 2026Review
- Prognostic value of lipoprotein(a) in a primary prevention ambulatory cohort.Clinical research in cardiology : official journal of the German Cardiac Society · 2026Article
- Clinician awareness, testing, and treatment for lipoprotein(a): Results from a large US national survey.American journal of preventive cardiology · 2026Article
- Third Year in Review, Fourth Year in Preview, and the 2025Journal of the American Heart Association · 2026Article
13 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
Background Despite its high prevalence and clinical significance, clinical measurement of lipoprotein(a) is rare but has not been systematically quantified. We assessed the prevalence of lipoprotein(a) testing overall, in those with various cardiovascular disease (CVD) conditions and in those undergoing cardiac testing across 6 academic medical centers associated with the University of California, in total and by year from 2012 to 2021. Methods and Results In this observational study, data from the University of California Health Data Warehouse on the number of individuals with unique lipoprotein(a) testing, unique CVD diagnoses (using
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.